Last edition
News about "RIPTAC Platform"
J&J Reports 75 Percent Tumor Response with JNJ-6143 in Prostate Cancer
Johnson & Johnson has reported 75 percent tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC molecule.
RIPTAC Platform | 27/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members